Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

B Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ — Pinetree Therapeutics, Inc. (“Pinetree”), a biotechnology company pioneering next-generation targeted…
posteditor
posteditor
Articles: 17424

Other News